Karachi: GlaxoSmithKline Pakistan Limited has scheduled a Board of Directors meeting for October 28, 2024, to review the company’s financial results for the quarter ending September 30, 2024. The meeting will take place in Karachi.

The company has also announced a close period from October 22, 2024, to October 28, 2024, during which no insider trading is allowed. This close period is in compliance with clause 5.6.4 of the Rule Book of the Pakistan Stock Exchange.

During this period, directors, the chief executive officer, the chief financial officer, the company secretary, substantial shareholders, and other executives of the company, along with their spouses, are prohibited from buying or selling company shares. This restriction is also extended to all employees, who have been duly informed about the close period.

According to information available from the Pakistan Stock Exchange (PSX), this close period is a standard practice to prevent any misuse of undisclosed financial performance information that could influence the stock price. The TRE Certificate Holders of the Exchange have been informed as per the regulatory requirements.